MCID: SYS004
MIFTS: 62

Systemic Mastocytosis malady

Categories: Rare diseases, Blood diseases

Aliases & Classifications for Systemic Mastocytosis

About this section

Aliases & Descriptions for Systemic Mastocytosis:

Name: Systemic Mastocytosis 32 10 45 12
Systemic Mast Cell Disease 45 24
Mastocytosis, Systemic 36 65
Corneal Dystrophy, Subepithelial Mucinous 65
 
Smcd - Systemic Mast Cell Disease 10
Systemic Tissue Mast Cell Disease 10
Mastocytosis Systemic 47
Smcd 45

Classifications:



External Ids:

Disease Ontology10 DOID:349
MeSH36 D034721
NCIt42 C9235
UMLS65 C0221013, C2748503

Summaries for Systemic Mastocytosis

About this section
NIH Rare Diseases:45 Systemic mastocytosis (sm) is a form of mastocytosis in which mast cells accumulate in internal organs such as the liver, spleen, bone marrow, and small intestines. the signs and symptoms vary based on which part(s) of the body are affected. sm is typically diagnosed in adults. it is usually caused by changes (mutations) in the kit gene. most cases are caused by somatic mutations which are not inherited or passed on to the next generation; however, it can rarely affect more than one family member. treatment is based on the signs and symptoms present in each person. last updated: 6/17/2015

MalaCards based summary: Systemic Mastocytosis, also known as systemic mast cell disease, is related to indolent systemic mastocytosis and aggressive systemic mastocytosis, and has symptoms including urticaria, abnormality of eosinophils and nausea and vomiting. An important gene associated with Systemic Mastocytosis is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways are Regulation of KIT signaling and Kit Receptor Signaling Pathway. Affiliated tissues include bone, bone marrow and liver, and related mouse phenotypes are tumorigenesis and limbs/digits/tail.

Related Diseases for Systemic Mastocytosis

About this section

Diseases in the Mastocytosis family:

systemic mastocytosis

Diseases related to Systemic Mastocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 165)
idRelated DiseaseScoreTop Affiliating Genes
1indolent systemic mastocytosis33.6CD2, KIT
2aggressive systemic mastocytosis31.8ASXL1, CD2, FIP1L1, KIT, PDGFRA
3thrombocytosis29.7JAK2, PDGFRB
4hematopoietic stem cell transplantation29.4JAK2, KIT, KITLG, PDGFRB
5myelodysplastic syndrome28.3ASXL1, JAK2, KIT, KITLG, PDGFRB, TET2
6mast cell neoplasm27.8CD2, FIP1L1, KIT, KITLG, PDGFRA
7smouldering systemic mastocytosis12.1
8systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease12.1
9sm-ahnmd11.6
10subepithelial mucinous corneal dystrophy11.4
11mastocytosis11.4
12metaphyseal chondrodysplasia, schmid type11.3
13mast-cell leukemia10.7
14extraneural perineurioma10.6KIT, PDGFRA
15ovarian cystic teratoma10.6KIT, TET2
16rhinitis10.6KIT, PDGFRA
17prostate leiomyosarcoma10.6KIT, PDGFRA
18bartholin's gland small cell carcinoma10.6KIT, PDGFRA
19carnitine palmitoyltransferase i deficiency , muscle10.6KIT, PDGFRA
20pediatric fibrosarcoma10.6KIT, PDGFRA
21ovary leiomyosarcoma10.6KIT, PDGFRA
22caroli disease10.5KIT, PDGFRA
23malignant fibroxanthoma10.5IFNA2, KIT
24comedo carcinoma10.5KIT, PDGFRA
25acute basophilic leukemia10.5ASXL1, TET2
26bone angioendothelial sarcoma10.5KIT, PDGFRA
27exencephaly10.5KIT, KITLG
28gallbladder leiomyosarcoma10.5IFNA2, KIT
29corticosterone methyloxidase deficiency10.5JAK2, KIT
30leukemia10.5
31megalocornea10.5KIT, KITLG
32olfactory nerve disease10.5KIT, KITLG
33hypereosinophilic syndrome, idiopathic, resistant to imatinib10.4IFNA2, KIT, TET2
34basal ganglia calcification, idiopathic, 410.4IFNA2, PDGFRB
35small cell neuroendocrine carcinoma10.4KIT, PDGFRA
36waardenburg's syndrome10.3KIT, KITLG
37heart cancer10.3IFNA2, JAK2
38ewing's family of tumors10.3IFNA2, JAK2, TET2
39thymus large cell carcinoma10.3FGFR1, KIT, PDGFRA
40trabecular follicular adenocarcinoma10.3FIP1L1, PDGFRA
41male reproductive system disease10.3IFNA2, KIT, KITLG
42megakaryocytic tumor10.3IFNA2, JAK2
43fallopian tube transitional cell carcinoma10.3KIT, PDGFRA
44osteoporosis10.3
45classic hodgkin lymphoma, mixed cellularity type10.3ASXL1, JAK2, TET2
46myeloid leukemia10.2
47total anomalous pulmonary venous return10.2KIT, KITLG, PDGFRA
48vesicoureteral reflux10.2KIT, KITLG, PDGFRA
49basilar artery insufficiency10.2ASXL1, JAK2, TET2
50lymphoma10.2

Graphical network of the top 20 diseases related to Systemic Mastocytosis:



Diseases related to systemic mastocytosis

Symptoms for Systemic Mastocytosis

About this section

HPO human phenotypes related to Systemic Mastocytosis:

(show all 30)
id Description Frequency HPO Source Accession
1 urticaria hallmark (90%) HP:0001025
2 abnormality of eosinophils hallmark (90%) HP:0001879
3 nausea and vomiting hallmark (90%) HP:0002017
4 malabsorption hallmark (90%) HP:0002024
5 abdominal pain hallmark (90%) HP:0002027
6 migraine hallmark (90%) HP:0002076
7 mastocytosis hallmark (90%) HP:0100495
8 skin rash typical (50%) HP:0000988
9 thrombocytopenia typical (50%) HP:0001873
10 leukopenia typical (50%) HP:0001882
11 anemia typical (50%) HP:0001903
12 reduced bone mineral density typical (50%) HP:0004349
13 impaired temperature sensation typical (50%) HP:0010829
14 increased bone mineral density typical (50%) HP:0011001
15 cirrhosis occasional (7.5%) HP:0001394
16 portal hypertension occasional (7.5%) HP:0001409
17 ascites occasional (7.5%) HP:0001541
18 sudden cardiac death occasional (7.5%) HP:0001645
19 splenomegaly occasional (7.5%) HP:0001744
20 asthma occasional (7.5%) HP:0002099
21 hepatomegaly occasional (7.5%) HP:0002240
22 acute leukemia occasional (7.5%) HP:0002488
23 bone pain occasional (7.5%) HP:0002653
24 lymphadenopathy occasional (7.5%) HP:0002716
25 recurrent fractures occasional (7.5%) HP:0002757
26 osteolysis occasional (7.5%) HP:0002797
27 arthralgia occasional (7.5%) HP:0002829
28 myalgia occasional (7.5%) HP:0003326
29 abnormality of the gastric mucosa occasional (7.5%) HP:0004295
30 bone marrow hypocellularity occasional (7.5%) HP:0005528

UMLS symptoms related to Systemic Mastocytosis:


pathergy reaction

Drugs & Therapeutics for Systemic Mastocytosis

About this section

Drugs for Systemic Mastocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 63)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Imatinib MesylatePhase 4, Phase 1, Phase 2577123596
2Protein Kinase InhibitorsPhase 4, Phase 1, Phase 23162
3
Cladribineapproved, investigationalPhase 2, Phase 3674291-63-820279
Synonyms:
(2R,3S,5R)-5-(6-amino-2-Chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
2 Chlorodeoxyadenosine
2'-Deoxy-2-chloroadenosine
2-CdA
2-Chloro-2'-deoxy-beta-adenosine
2-Chloro-2'-deoxyadenosine
2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine
2-Chlorodeoxyadenosine
2-chloro-6-amino-9-(2-Deoxy-beta-D-erythro-pentofuranosyl)purine
2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine
2-chloro-Deoxyadenosine
2-chloro-deoxyadenosine
24757-90-2
2CdA
2ClAdo
4291-63-8
AC-7591
AC1L2FXP
Adenosine, 2-chloro-2'-deoxy
BRN 0624220
C10H12ClN5O3.C3H8
CHEBI:567361
CHEMBL1619
CID20279
CL9
CPD000058553
Chlorodeoxyadenosine
Cladarabine
Cladaribine
Cladribina
Cladribine
Cladribine (JAN/USAN/INN)
Cladribine [USAN:INN:BAN]
Cladribinum
 
CldAdo
D01370
D017338
DB00242
FT-0080707
HMS2052K13
HSDB 7564
LS-15109
Leustat
Leustatin
Leustatin (TN)
Leustatin, 2-chlorodeoxyadenosine, Cladribine
Litak
MLS000028377
MLS000028484
MLS000759397
MLS001077345
MolPort-002-054-532
MolPort-005-935-074
Movectro
Mylinax
NCGC00022567-05
NCGC00164384-01
NSC 105014
NSC 105014-F
NSC-105014
RWJ 26251
RWJ-26251
RWJ-26251-000
S1199_Selleck
SAM001246526
SMR000058553
UNII-47M74X9YT5
ZINC03798064
cladribina
cladribine
cladribinum
4Immunosuppressive AgentsPhase 2, Phase 3, Phase 110422
5Immunologic FactorsPhase 2, Phase 3, Phase 118483
6Contraceptives, OralPhase 2, Phase 33734
7
FludarabineapprovedPhase 2, Phase 1105921679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-Fluoro-ara AMP
2-Fluoroadenine arabinoside 5'-monophosphate
21679-14-1
2F-Ara-AMP
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
 
Fludara, Fludarabine
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine Phosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
Oforta
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
8
Denileukin diftitoxapproved, investigationalPhase 248173146-27-5
Synonyms:
DT
Diphtheria toxin precursor
 
NAD(+--diphthamide ADP- ribosyltransferase)
Ontak
denileukin diftitox
9
Cyclophosphamideapproved, investigationalPhase 2264350-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
10
Sunitinibapproved, investigationalPhase 2, Phase 1486341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib Malate
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
11
Mycophenolate mofetilapproved, investigationalPhase 1, Phase 2898128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate Mofetil
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
12
rituximabapprovedPhase 21582174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
13
PaclitaxelapprovedPhase 2262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
14
Mycophenolic acidapprovedPhase 1, Phase 289824280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Melbex
 
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolic Acid
Mycophenolsaeure
Myfortic
15
EverolimusapprovedPhase 21797159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Afinitor Disperz
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
VOTUBIA
Zortress
everolimus
16
Miconazoleapproved, investigationalPhase 2, Phase 1302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
17
Sirolimusapproved, investigationalPhase 2179753123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
18
VidarabineapprovedPhase 1, Phase 223824356-66-932326, 21704
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
ADENOSINE, U.S.P.
ADN
AI3-52413
AI3-52821
AR-1H6029
ARA-A NSC 247519
Ade-Rib
Adenine Arabinoside
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
Adenosine-8-14C
Adensoine
Ambap5536-17-4
Ara A
Ara-A
Ara-ATP
Araadenosine
Arabinoside Adenine
Arabinoside adenine
Arabinosyl Adenine
Arabinosyl adenine
Arabinosyl-adenine
Arabinosyladenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
Bio1_000437
Bio1_000926
Bio1_001415
Boniton
C00212
CAS-5536-17-4
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
Caswell No. 010B
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
 
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
LS-15059
LS-15085
Lopac0_000123
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC-404241
NSC247519
NSC404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
PDSP1_001036
PDSP2_001020
Pallacor
Polyadenosine
Polyriboadenosine
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
Prestwick_983
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
SPECTRUM1500107
SPECTRUM1500609
SR 96225
SR-96225
STK361815
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spectrum_001894
Spongoadenosine
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
VIRDARABINE
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
adenine-D-ribose
adenosine
alpha-Ara A
beta-Adenosine
beta-Ara A
beta-D-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
19
alemtuzumabapproved, investigationalPhase 2302216503-57-0
Synonyms:
Campath
 
Lemtrada
Mabcampath
alemtuzumab
20
Dasatinibapproved, investigationalPhase 2268302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anh. dasatinib
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
 
Dasatinibum
EC-000.2122
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
dasatinib
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
21StaurosporineexperimentalPhase 22162996-74-144120114
22Antimetabolites, AntineoplasticPhase 1, Phase 25770
23Vidarabine PhosphatePhase 1, Phase 2119
24Antirheumatic AgentsPhase 1, Phase 28496
25Calcineurin InhibitorsPhase 1, Phase 21223
26Antiviral AgentsPhase 1, Phase 28071
27Dermatologic AgentsPhase 1, Phase 24555
28CyclosporinsPhase 1, Phase 2873
29AntimetabolitesPhase 1, Phase 29454
30Analgesics, Non-NarcoticPhase 25184
31Interleukin-2Phase 2487
32AnalgesicsPhase 29358
33Anti-Infective AgentsPhase 2, Phase 117220
34Antibiotics, AntitubercularPhase 2, Phase 15971
35Antifungal AgentsPhase 2, Phase 13015
36Peripheral Nervous System AgentsPhase 218510
37Angiogenesis InhibitorsPhase 2, Phase 13688
38Anti-Bacterial AgentsPhase 2, Phase 19140
39Albumin-Bound PaclitaxelPhase 22621
40Fludarabine phosphatePhase 2, Phase 1105930751
41Angiogenesis Modulating AgentsPhase 2, Phase 13611
42AntibodiesPhase 24477
43Antibodies, MonoclonalPhase 22413
44ImmunoglobulinsPhase 24477
454'-N-benzoylstaurosporinePhase 223
46Cromolyn SodiumPhase 216
47tyrosineNutraceuticalPhase 2596
48
Valganciclovirapproved, investigational76175865-60-864147
Synonyms:
175865-60-8
5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one
AC1L20JF
AC1Q63EV
C14H22N6O5
CID64147
Cymeval
D02495
DB01610
I06-1704
L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester
 
L-Valine, ester with ganciclovir
L-valine, ester with ganciclovir
LS-173677
NCGC00168779-01
RO1079070/194
RS 79070
UNII-GCU97FKN3R
Valcyte
Valganciclovir
Valganciclovir (INN)
Valganciclovir (Oral)
Valganciclovir [INN:BAN]
[2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate
49
Ironapproved10217439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Dexiron
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Ed-In-Sol
 
Eisen
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feraheme
Feronate
Ferretts
Ferrlecit
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Infufer
Iron
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Yieronia
fer
ferrous ascorbate
ferrous fumarate
ferrous gluconate
ferrous glycine sulfate
ferrous iron
ferrous succinate
ferrous sulfate
hierro
50
Ganciclovirapproved, investigational14082410-32-03454
Synonyms:
106931-35-5
107910-75-8 (mono-hydrochloride salt)
2'-NDG
2'-Nor-2'-deoxyguanosine
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one
2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
82410-32-0
86357-12-2
9-((1,3-Dihydroxy-2-propoxy)methyl)guanine
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
96551-29-0
AC-12604
AC1L1FZ2
AC1Q52OB
AKOS004119898
BB_NC-1042
BIDD:GT0783
BIOLF-62
BPBio1_000877
BSPBio_000797
BW 759
BW 759U
BW-759U
BW-795
BW-B 759U
Biolf 62
CAS-82410-32-0
CCRIS 9212
CHEBI:465284
CHEMBL182
CID3454
CPD000058324
Citovirax
Cymevan
Cymeven
Cymevene
Cytovene
Cytovene (TN)
Cytovene IV
Cytovene-IV
D00333
DB01004
DRG-0018
EU-0100539
 
G 2536
G2536_SIGMA
GA2
GANCICLOVIR SODIUM
GCV & 1110U81
GCV & MSL
Ganciclovir
Ganciclovir & C34-dgA immunotoxin
Ganciclovir & D5-dgA immunotoxin
Ganciclovir (JAN/USP/INN)
Ganciclovir Sodium
Ganciclovir [USAN:INN:BAN:JAN]
Ganciclovirum
Ganciclovirum [Latin]
Gancyclovir
Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody
HHEMG
HMS1570H19
HMS2090K08
HSDB 6512
Hydroxyacyclovir
I07-0010
IN1478
LS-73939
Lopac-G-2536
Lopac0_000539
MB3795
MLS000028481
MLS001077349
MolPort-000-758-398
MolPort-002-507-301
NCGC00015471-01
NCGC00015471-02
NCGC00015471-03
NCGC00015471-06
NCGC00093928-01
NCGC00093928-02
NCGC00168567-01
PDSP1_000816
PDSP2_000803
Prestwick0_000839
Prestwick1_000839
Prestwick2_000839
Prestwick3_000839
Prestwick_1068
RS-21592
SAM002548936
SMP2_000038
SMR000058324
SPBio_002718
ST-605
STK801910
UNII-P9G3CKZ4P5
Virgan
Vitrasert
Vitrasert (TN)
ZINC00001505
Zirgan
ganciclovir
nchembio.87-comp3

Interventional clinical trials:

(show all 48)
idNameStatusNCT IDPhase
1Imatinib in KIT-negative Systemic MastocytosisActive, not recruitingNCT01297777Phase 4
2Study on Mastocytosis for Rupatadine TreatmentCompletedNCT01481909Phase 2, Phase 3
3Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic MastocytosisRecruitingNCT01602939Phase 2, Phase 3
4A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With HandicapRecruitingNCT00814073Phase 3
5Everolimus (RAD001) as Therapy for Patients With Systemic MastocytosisCompletedNCT00449748Phase 2
6Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)CompletedNCT00493129Phase 2
7A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related CancersCompletedNCT00109707Phase 1, Phase 2
8Thalidomide in Treating Patients With Relapsed or Progressive Systemic MastocytosisCompletedNCT00769587Phase 2
917-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic MastocytosisCompletedNCT00132015Phase 2
10Stem Cell Transplantation to Treat Systemic MastocytosisCompletedNCT00006413Phase 2
11Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
12Efficacy of AB1010 in Patients With Systemic Indolent MastocytosisCompletedNCT00831974Phase 2
13Efficacy and Safety of TF002 in Cutaneous MastocytosisCompletedNCT00457288Phase 2
14Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHDCompletedNCT00186628Phase 2
15Ibrutinib in Treating Patients With Advanced Systemic MastocytosisRecruitingNCT02415608Phase 2
16SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)RecruitingNCT02268253Phase 1, Phase 2
17Sunitinib® in Patients With Recurrent Ovarian Clear Cell CarcinomaRecruitingNCT01824615Phase 2
18Treatment of Indolent Systemic Mastocytosis With PA101Active, not recruitingNCT02478957Phase 2
19Midostaurin in Indolent Systemic MastocytosisActive, not recruitingNCT01920204Phase 2
20Phase II Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell LeukemiaActive, not recruitingNCT00233454Phase 2
21Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell LeukemiaActive, not recruitingNCT00782067Phase 2
22Imatinib Mesylate (Gleevec) in the Treatment of Systemic SclerosisActive, not recruitingNCT00555581Phase 2
23Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic CancerActive, not recruitingNCT00006251Phase 1, Phase 2
24Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerActive, not recruitingNCT00118352Phase 2
25Evaluation of Response of Dasatinib to Treat MastocytosisNot yet recruitingNCT00979160Phase 2
26Obatoclax for Systemic MastocytosisTerminatedNCT00918931Phase 2
27Sunitinib in Treating Patients With Idiopathic MyelofibrosisTerminatedNCT00387426Phase 2
28Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
29MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
30Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid MalignanciesRecruitingNCT02561988Phase 1
31A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesRecruitingNCT02571036Phase 1
32Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy IndividualsCompletedNCT00001760
33Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593
34Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantCompletedNCT01199562
35Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766
36Cause and Natural Course of Pediatric-Onset MastocytosisCompletedNCT00050193
37Patient-Reported Outcome Questionnaire for Systemic MastocytosisRecruitingNCT02380222
38Diagnostic Value of Bone Marrow Tryptase in Systemic MastocytosisRecruitingNCT02441166
39Use of Tamoxifen in Systemic MastocytosisRecruitingNCT01334996
40Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell LeukemiaRecruitingNCT01807598
41Study of Mast Cell PrecursorsRecruitingNCT00001756
42Mast Cell Connect: A Registry for Patients With MastocytosisRecruitingNCT02620254
43Molecular Mechanisms and Diagnosis of MastocytosisRecruitingNCT00336076
44Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute LeukemiaRecruitingNCT01869777
45Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With CancerRecruitingNCT00898079
46Pregnancy and Medically Assisted Conception in Rare DiseasesRecruitingNCT02450396
47Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerActive, not recruitingNCT01053494
48Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciesActive, not recruitingNCT00014235

Search NIH Clinical Center for Systemic Mastocytosis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Systemic Mastocytosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Systemic Mastocytosis:
Peripheral blood-derived hematopoietic stem cells for treatment of systemic mastocytosis
Embryonic/Adult Cultured Cells Related to Systemic Mastocytosis:
Peripheral blood-derived hematopoietic stem cells (family), PMID: 10498605


Cochrane evidence based reviews: mastocytosis, systemic

Genetic Tests for Systemic Mastocytosis

About this section

Anatomical Context for Systemic Mastocytosis

About this section

MalaCards organs/tissues related to Systemic Mastocytosis:

33
Bone, Bone marrow, Liver, Myeloid, Small intestine, Spleen, Skin

Animal Models for Systemic Mastocytosis or affiliated genes

About this section

MGI Mouse Phenotypes related to Systemic Mastocytosis:

38 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.8ASXL1, JAK2, KIT, KITLG, PDGFRA, TET2
2MP:00053718.8FGFR1, KIT, KITLG, PDGFRA, PDGFRB
3MP:00053808.4FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB
4MP:00053818.1ASXL1, FGFR1, KIT, KITLG, PDGFRA, PDGFRB
5MP:00053828.1ASXL1, FGFR1, KIT, KITLG, PDGFRA, PDGFRB
6MP:00107717.9FGFR1, HDC, JAK2, KIT, KITLG, PDGFRA
7MP:00028737.8CD2, FGFR1, JAK2, KIT, PDGFRA, PDGFRB
8MP:00053797.6ASXL1, FGFR1, JAK2, KIT, KITLG, PDGFRA
9MP:00053847.5ASXL1, FGFR1, JAK2, KIT, KITLG, PDGFRA
10MP:00053907.2ASXL1, FGFR1, JAK2, KIT, KITLG, PDGFRA
11MP:00053786.9ASXL1, FGFR1, HDC, JAK2, KIT, KITLG
12MP:00053876.7ASXL1, FGFR1, HDC, JAK2, KIT, KITLG
13MP:00053976.6ASXL1, FGFR1, HDC, JAK2, KIT, KITLG

Publications for Systemic Mastocytosis

About this section

Articles related to Systemic Mastocytosis:

(show top 50)    (show all 596)
idTitleAuthorsYear
1
Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis. (27042302)
2016
2
Systemic mastocytosis: Evolving lessons from large patient registry datasets. (27102564)
2016
3
The Basophil Activation Test Is Not a Useful Screening Tool for Hymenoptera Venom-Related Anaphylaxis in Patients with Systemic Mastocytosis. (27055231)
2016
4
Systemic mastocytosis presenting as IgE-mediated food-induced anaphylaxis: a report of two cases. (25687289)
2015
5
Mast Cells in Systemic Mastocytosis Have Distinctly Brighter CD45 Expression by Flow Cytometry. (25780004)
2015
6
Rapid skeletal turnover in radiographic mimic of osteopetrosis might be secondary to systemic mastocytosis. (25639963)
2015
7
Orbital Involvement in Systemic Mastocytosis. (24410676)
2014
8
Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease (SM-AHNMD) in an infant patient. (25099159)
2014
9
Omalizumab Induced Remission of Idiopathic Anaphylaxis in a Patient Suffering from Indolent Systemic Mastocytosis. (24162824)
2013
10
Systemic mastocytosis - the importance of looking within bone marrow fragments. (24123109)
2013
11
Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). (23675567)
2013
12
Systemic mastocytosis presenting as Kounis syndrome. (24267372)
2013
13
Isolated splenomegaly as the only presentation of systemic mastocytosis. (23604430)
2013
14
KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells. (23743299)
2013
15
Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. (23181448)
2013
16
Systemic mastocytosis: disease overview, pathogenesis, and treatment. (23009941)
2012
17
Smouldering systemic mastocytosis presenting with cryptic life-threatening crises: case report and literature review. (22408224)
2012
18
Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. (22123213)
2012
19
Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review. (22742558)
2012
20
Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. (22370312)
2012
21
Current approaches to the diagnosis and treatment of systemic mastocytosis. (20143640)
2010
22
Treatment of aggressive systemic mastocytosis with daclizumab. (20038223)
2010
23
Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. (19116630)
2009
24
Systemic mastocytosis presenting as osteoporosis--a case report. (19305945)
2009
25
A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. (16400343)
2006
26
Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. (15995323)
2005
27
Systemic mastocytosis]. (16334197)
2005
28
Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient? (14983941)
2004
29
Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. (14687620)
2004
30
Multiple life-threatening fainting episodes: fatal systemic mastocytosis. (14719479)
2003
31
Comment on systemic mastocytosis study. (12716379)
2003
32
Systemic Mastocytosis. (12521570)
2003
33
Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to recently established SM-criteria. (12002761)
2002
34
Effect of granulocyte macrophage colony-stimulating factor in a patient with benign systemic mastocytosis. (11703299)
2001
35
Pathologic quiz case. Systemic mastocytosis. (10747334)
2000
36
Hematologic aspects of systemic mastocytosis. (10909040)
2000
37
Gastrointestinal abnormalities and involvement in systemic mastocytosis. (10909042)
2000
38
The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. (9133977)
1997
39
Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. (8605279)
1996
40
Pulmonary and ovarian manifestations of systemic mastocytosis. (8610583)
1996
41
Anti-interferon-gamma antibodies in a patient undergoing interferon-gamma treatment for systemic mastocytosis. (8836917)
1996
42
Portal hypertension and ascites in systemic mastocytosis. (2608581)
1989
43
Treatment of adult systemic mastocytosis with a PAF-acether antagonist BN52063. (2898694)
1988
44
Hypotensive attacks due to systemic mastocytosis. (3591218)
1987
45
Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption. (3606906)
1987
46
Effects of isoprenaline and terbutaline on urinary excretion of histamine and its two main metabolites in systemic mastocytosis. (3728212)
1986
47
Failure of sulfites to produce clinical responses in patients with systemic mastocytosis or recurrent anaphylaxis: results of a single-blind study. (3905921)
1985
48
Secretory diarrhea and prostaglandin D2 overproduction in systemic mastocytosis. (6953312)
1982
49
50

Variations for Systemic Mastocytosis

About this section

Expression for genes affiliated with Systemic Mastocytosis

About this section
Search GEO for disease gene expression data for Systemic Mastocytosis.

Pathways for genes affiliated with Systemic Mastocytosis

About this section

Pathways related to Systemic Mastocytosis according to GeneCards Suite gene sharing:

(show all 25)
idSuper pathwaysScoreTop Affiliating Genes
19.9KIT, KITLG
2
Show member pathways
9.5JAK2, KIT, KITLG
39.4PDGFRA, PDGFRB
4
Show member pathways
9.4PDGFRA, PDGFRB
59.3CD2, KIT, KITLG
6
Show member pathways
9.0FGFR1, KIT, PDGFRB
78.9FGFR1, PDGFRA, PDGFRB
88.9FGFR1, PDGFRA, PDGFRB
9
Show member pathways
8.9FGFR1, PDGFRA, PDGFRB
108.9CD2, IFNA2, KIT, KITLG
11
Show member pathways
8.8KIT, KITLG, PDGFRA, PDGFRB
128.7FGFR1, KIT, PDGFRA, PDGFRB
13
Show member pathways
8.6FGFR1, JAK2, PDGFRA, PDGFRB
14
Show member pathways
8.4JAK2, KIT, KITLG, PDGFRA, PDGFRB
15
Show member pathways
8.4FGFR1, KIT, KITLG, PDGFRA, PDGFRB
16
Show member pathways
8.4FGFR1, KIT, KITLG, PDGFRA, PDGFRB
178.4FGFR1, KIT, KITLG, PDGFRA, PDGFRB
18
Show member pathways
8.4FGFR1, KIT, KITLG, PDGFRA, PDGFRB
19
Show member pathways
8.0FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB
20
Show member pathways
8.0FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB
217.6FGFR1, IFNA2, JAK2, KIT, KITLG, PDGFRA
22
Show member pathways
7.4CD2, FGFR1, JAK2, KIT, KITLG, PDGFRA
23
Show member pathways
7.4CD2, FGFR1, JAK2, KIT, KITLG, PDGFRA
24
Show member pathways
7.0CD2, FGFR1, IFNA2, JAK2, KIT, KITLG
25
Show member pathways
7.0CD2, FGFR1, IFNA2, JAK2, KIT, KITLG

GO Terms for genes affiliated with Systemic Mastocytosis

About this section

Biological processes related to Systemic Mastocytosis according to GeneCards Suite gene sharing:

(show all 29)
idNameGO IDScoreTop Affiliating Genes
1myeloid progenitor cell differentiationGO:000231810.6KIT, TET2
2positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.5JAK2, KIT
3ovarian follicle developmentGO:000154110.4KIT, KITLG
4positive regulation of DNA replicationGO:004574010.2KITLG, PDGFRA
5positive regulation of tyrosine phosphorylation of Stat3 proteinGO:004251710.1IFNA2, JAK2, KIT
6cytokine-mediated signaling pathwayGO:001922110.0IFNA2, JAK2, KIT
7retina vasculature development in camera-type eyeGO:00612989.9PDGFRA, PDGFRB
8transmembrane receptor protein tyrosine kinase signaling pathwayGO:00071699.6KIT, PDGFRA, PDGFRB
9intracellular signal transductionGO:00355569.6JAK2, KIT, PDGFRB
10platelet-derived growth factor receptor signaling pathwayGO:00480089.5JAK2, PDGFRA, PDGFRB
11positive regulation of phosphatidylinositol 3-kinase activityGO:00435529.5KIT, PDGFRA, PDGFRB
12cell chemotaxisGO:00603269.4KIT, PDGFRA, PDGFRB
13positive regulation of phospholipase C activityGO:00108639.3FGFR1, KIT, PDGFRA, PDGFRB
14positive regulation of MAP kinase activityGO:00434069.2FGFR1, KIT, KITLG, PDGFRB
15Ras protein signal transductionGO:00072659.2FGFR1, JAK2, PDGFRB
16regulation of phosphatidylinositol 3-kinase signalingGO:00140669.2FGFR1, KITLG, PDGFRA, PDGFRB
17vascular endothelial growth factor receptor signaling pathwayGO:00480109.1FGFR1, JAK2, KIT, KITLG, PDGFRA
18positive regulation of GTPase activityGO:00435479.0JAK2, KIT, KITLG, PDGFRB
19MAPK cascadeGO:00001658.9FGFR1, JAK2, KIT, PDGFRB
20phosphatidylinositol-mediated signalingGO:00480158.9FGFR1, KIT, KITLG, PDGFRA, PDGFRB
21Fc-epsilon receptor signaling pathwayGO:00380958.8FGFR1, PDGFRA, PDGFRB
22positive regulation of phosphatidylinositol 3-kinase signalingGO:00140688.8FGFR1, JAK2, KIT, PDGFRA, PDGFRB
23protein autophosphorylationGO:00467778.8FGFR1, JAK2, KIT, PDGFRA, PDGFRB
24axon guidanceGO:00074118.6FGFR1, JAK2, KIT, PDGFRB
25fibroblast growth factor receptor signaling pathwayGO:00085438.4FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB
26activation of MAPKK activityGO:00001868.3FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB
27insulin receptor signaling pathwayGO:00082868.3FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB
28neurotrophin TRK receptor signaling pathwayGO:00480118.2FGFR1, JAK2, KITLG, PDGFRB
29innate immune responseGO:00450878.0FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB

Molecular functions related to Systemic Mastocytosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1platelet-derived growth factor bindingGO:00484079.5PDGFRA, PDGFRB
2vascular endothelial growth factor bindingGO:00380859.4PDGFRA, PDGFRB
3protein tyrosine kinase activityGO:00047138.7FGFR1, KIT, PDGFRA, PDGFRB

Sources for Systemic Mastocytosis

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet